UY35211A - Compuestos tricíclicos - Google Patents

Compuestos tricíclicos

Info

Publication number
UY35211A
UY35211A UY0001035211A UY35211A UY35211A UY 35211 A UY35211 A UY 35211A UY 0001035211 A UY0001035211 A UY 0001035211A UY 35211 A UY35211 A UY 35211A UY 35211 A UY35211 A UY 35211A
Authority
UY
Uruguay
Prior art keywords
tricyclic compounds
present
provides
compound
formula
Prior art date
Application number
UY0001035211A
Other languages
English (en)
Inventor
Mckenna Jeffrey
Ahmed Mahbub
Alexander Ashall-Kelly
Gueritz Louisa
Mckenna Joseph
Mutton Simon
Parmar Rakesh
Shepherd Jon
Wright Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35211(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY35211A publication Critical patent/UY35211A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo y sus usos terapéuticos. El presente invento además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
UY0001035211A 2012-12-19 2013-12-19 Compuestos tricíclicos UY35211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US201361906141P 2013-11-19 2013-11-19

Publications (1)

Publication Number Publication Date
UY35211A true UY35211A (es) 2014-07-31

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035211A UY35211A (es) 2012-12-19 2013-12-19 Compuestos tricíclicos

Country Status (25)

Country Link
US (2) US9359381B2 (es)
EP (1) EP2935278B1 (es)
JP (1) JP6284546B2 (es)
KR (1) KR20150097660A (es)
CN (1) CN105143230B (es)
AP (1) AP2015008539A0 (es)
AR (1) AR094122A1 (es)
AU (1) AU2013365739A1 (es)
BR (1) BR112015014292A2 (es)
CA (1) CA2895660A1 (es)
CL (1) CL2015001730A1 (es)
CR (1) CR20150325A (es)
CU (1) CU20150066A7 (es)
EA (1) EA201591177A1 (es)
ES (1) ES2628369T3 (es)
HK (1) HK1209741A1 (es)
IL (1) IL239389A0 (es)
MX (1) MX2015007939A (es)
PE (1) PE20151055A1 (es)
PH (1) PH12015501386A1 (es)
SG (1) SG11201504594QA (es)
TN (1) TN2015000279A1 (es)
TW (1) TW201429974A (es)
UY (1) UY35211A (es)
WO (1) WO2014097148A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2014097147A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
PE20151055A1 (es) 2012-12-19 2015-08-05 Novartis Ag Compuestos triciclicos para inhibir el canal cftr
EP3194469B1 (en) * 2014-09-19 2019-06-12 Momentive Performance Materials Inc. Platinum (ii) diene complexes for controlled siloxane crosslinking
CN106478558B (zh) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法
MX2023012852A (es) 2021-04-29 2024-01-15 Novartis Ag Quimeras que tienen como diana la desubiquitinasa y metodos relacionados.
CN117654560B (zh) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 一种通过氧化氨基连续化制备硝基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014386A1 (fr) 1999-08-25 2001-03-01 Banyu Pharmaceutical Co., Ltd. Nouveaux dérivés isoindole
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
US20110015137A1 (en) * 2007-07-05 2011-01-20 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011019737A1 (en) * 2009-08-10 2011-02-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9062073B2 (en) * 2011-05-27 2015-06-23 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2014097147A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
PE20151055A1 (es) 2012-12-19 2015-08-05 Novartis Ag Compuestos triciclicos para inhibir el canal cftr

Also Published As

Publication number Publication date
PH12015501386A1 (en) 2015-09-02
HK1209741A1 (en) 2016-04-08
TN2015000279A1 (en) 2016-10-03
EP2935278A1 (en) 2015-10-28
US20150336986A1 (en) 2015-11-26
KR20150097660A (ko) 2015-08-26
SG11201504594QA (en) 2015-07-30
EP2935278B1 (en) 2017-03-15
ES2628369T3 (es) 2017-08-02
AU2013365739A1 (en) 2015-07-09
CL2015001730A1 (es) 2015-08-28
CA2895660A1 (en) 2014-06-26
MX2015007939A (es) 2016-03-11
CR20150325A (es) 2015-08-10
US20140171417A1 (en) 2014-06-19
AP2015008539A0 (en) 2015-06-30
CN105143230A (zh) 2015-12-09
EA201591177A1 (ru) 2015-11-30
CU20150066A7 (es) 2015-11-27
WO2014097148A1 (en) 2014-06-26
PE20151055A1 (es) 2015-08-05
JP2016509579A (ja) 2016-03-31
WO2014097148A9 (en) 2015-02-19
AR094122A1 (es) 2015-07-08
JP6284546B2 (ja) 2018-02-28
BR112015014292A2 (pt) 2017-07-11
CN105143230B (zh) 2017-06-09
US9359381B2 (en) 2016-06-07
IL239389A0 (en) 2015-07-30
TW201429974A (zh) 2014-08-01

Similar Documents

Publication Publication Date Title
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
UY35209A (es) Compuestos tricíclicos
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
UY35211A (es) Compuestos tricíclicos
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
IN2015DN00185A (es)
CU20130094A7 (es) Moduladores de la vía del complemento
CO6781541A2 (es) Derivados glucósidos y usos de los mismos
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
UY36124A (es) Derivados de carboxamida
UY33348A (es) Compuestos de furopiridina y usos de los mismos
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
GT201400042A (es) Compuesto de benzotiazolona
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
UY33857A (es) Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos.
CU20160170A7 (es) Derivados de carboxamida
UY35792A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210715